Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, disposed of a block of common stock in mid-March as part of a prearranged trading program and concurrently exercised a set of stock options, filings show.
According to a Form 4 submitted to the Securities and Exchange Commission, Rodman sold a total of 20,406 shares of Mineralys Therapeutics (NASDAQ: MLYS) on March 12 and 13, 2026. The sale generated approximately $542,973 in proceeds, with the transactions executed at weighted average prices spanning $25.9111 to $27.82 per share. The filing indicates these trades were carried out under a Rule 10b5-1 plan that was adopted on October 6, 2025.
On those same dates, Rodman also exercised stock options to acquire 14,057 shares of common stock. The exercises involved option strike prices ranging from $1.08 to $14.25 and required total cash outlay of $102,363.
Market context for the trades: Mineralys shares are quoted at $25.73, representing an 84% increase over the past 12 months. At the same time, InvestingPro analysis flagged the stock as appearing overvalued at current levels.
Financial reporting and clinical program updates have shaped recent investor dialogue. Mineralys reported fourth-quarter 2025 results with an earnings per share (EPS) of -0.4, outperforming expectations of -0.94. Despite the EPS beat, the company is confronting investor concerns tied to higher general and administrative expenses and the implications of recent trial data.
Analyst responses to Mineralys' trajectory diverge. BofA Securities raised its price target on the company to $51.00 and kept a Buy rating, citing clinical development updates for the lead candidate, lorundrostat. Stifel reiterated a Buy rating with a $52.00 price target, emphasizing the company’s preparations for a commercial launch in the wake of the FDA’s acceptance of the New Drug Application for lorundrostat.
Not all brokerages are bullish. Jefferies trimmed its price target to $30 but maintained a Hold rating, pointing to strategic uncertainty around the path for lorundrostat. Jefferies noted that Mineralys is weighing multiple options - including mergers and acquisitions, partnerships, or an independent launch - as it plans toward the December PDUFA date.
The combination of insider sales executed under a Rule 10b5-1 program, option exercises, a recent EPS outperformance, and mixed analyst guidance underscores the complex near-term picture for Mineralys. Investors seeking deeper analysis and fuller context on the company’s financials and insider activity are directed to the comprehensive Pro Research Report available on InvestingPro for this equity and more than 1,400 other U.S. stocks.
What this means
Rodman’s actions—planned sales under a 10b5-1 arrangement plus option exercises—reflect routine insider liquidity and equity compensation mechanics coinciding with advancing clinical and regulatory events tied to lorundrostat. At the same time, the company’s recent financial and operational updates have elicited divergent analyst views on valuation and strategy.